XP_001682355.1 XP_814406.1 XP_844906.1 NP_001118295.1 sp Q5VZE5 NAA35_HUMAN NP_579858.1	CDLNDTWEDVLTAFNDCLK-GESTWSCHCLDG 	31 34 34 57 53 53
XP_001682355.1 XP_814406.1 XP_844906.1 NP_001118295.1 sp Q5VZE5 NAA35_HUMAN NP_579858.1	IDKEVILSAPEIMDPKTDSGFNCEEIYSLSHLLKTEEVPSAATVSTEAALLD VEKETMLSAPEVMDAKTDPGCGYGSICSLNCLLKDGTIPSAATLTG-EALLD VDKEAMLSAPEVMDAKTDPGCGYAQIRSLNDLLAKGDIPSAATLQG-QELLD FNLFAAMSALEIMDPKMDSGMVSTFYSIDEAIESGFAPVPISSDSTVN-VQSIID FGLFEAMSAIEMMDPKMDAGMIGNQVNRKVLNFEQAIKDGTIKIKDLT-LPELIG FGLFEAMSAIEMMDPKMDAGMIGNQVNRKVLNFEQAVKDGTIKIKDLS-LPELIG :** *:** * * * :::::::::::::::::::::::	83 85 85 111 107 107
XP_001682355.1 XP_814406.1 XP_844906.1 NP_001118295.1 splQ5VZE5 NAA35_HUMAN NP_579858.1	VMDYIHVKELTYLQGYSLTQSYLDFPYFLRMDLLKGQNSTLHAYCRGVLRSLDCVLHAVF VMDLIHLKELNYLQGFSLTSGCLEFSYFFCMDLLKEQNLTLYTYCRALARCIDLITTRAVM VMDLILAKELQYLQGFSLTSGCLAFPYFFKMDLLKEQNPVLHAYCRGVVRTVEIVLRAVM IMDHLLACEATWHMGHSLAQTVFSCIYVLRPERTSSQ-ALHSYCRVIRATCRAVVSVVS IMDTCFCCLITWLEGHSLAQTVFTCLYIHNPDFIEDP-AM-KAFALGILKICDIAREKVN IMDTCFCCLITWLEGHSLAQTVFTCLYIHNPDFIEDP-AM-KAFALGILKICDIAREKVN :** : *.**: : *. : *. : *. : * : * : *	143 145 145 170 165 165

## B

NP_010946.3 NP_001317040.1 XP_003722006.1	IDYKLRVLTQDGRVYIGQLMAFDKHMNLVLNECIEERVPKTQLDKLRPRKD -ARQQLEALLNKTMRIRMTDGRTLVGCFLCTDRDCNVILGSAQEFLKPSDSF MGKYTMLHNINKVLCVMLDDGRTVTGKLLVFDKHMNVVLGDAVEERPQSKKMAEE	51 51 55
XP 808107.1	MGRESMLHNINRTLRIVLIDGRELTGKLLVYDRHMNVVLGDATESREETKKMKEA	55
XP_951644.1	MGHQNMLHNINRTLRVTLVDGREMTGKMLLFDKFMNVVLADTVETRKETKKMKDA	55
NP 010946.3	SKDGTTLNIKVEKRVLGLTILRGEQILSTVV	82
NP 001317040.1	SAGEPRVLGLAMVPGHHIVSIEVSAGEPRVLGLAMVPGHHIVSIEV	74
XP_003722006.1	GVSSKRQLGLILLRGEHVVSVTVMKDSENGGSGAVANFGGAPKLAK	101
XP_808107.1	GISPQRSLGLVLLRGVHVISVNVLGASENNGDGEGKTKGQPANFEKAPRAKV	107
XP_951644.1	GISPQRKLGMILLRGEYVVAVSVLKDNVSEDKAQPANFESATREKL	101
_		

\* \*\*: :: \* ::: \*

A

	<u>↓</u> ↓ #	
NP 011877.1	TYRRMGIAENLMRQALFALREVHQAEYVSLHVRQSNRAALHLYRDTLAFEVLSIEKSYYQ	180
NP 003482.1	SHRRLGLAQKLMDQASRAMIENFNAKYVSLHVRKSNRAALHLYSNTLNFQISEVEPKYYA	139
XP_001681770.1	SHRKLGIASRVMRATMKEMDAEYGAHYCSLHVRKTNDAALHLYQDTLGFRCVGVEEKYYM	140
XP 817467.1	THRRLGIASRVMRASMKEMEKEYDANYCSLHVRKTNDAALHLYQETLGFRCANVEKGYYV	140
XP 828529.1	THRRLGIASRVMNAALHEMEHEYDANFCSLHVRKTNDAALHLYONTLNFRCANVESKYYV	140
-	::*::*:*:* : : . *.: *****::* ****** <sup>-</sup> :** *. :* **	
NP_011877.1	DGEDAYAMKKVLK	193
NP_003482.1	DGEDAYAMKR	149
XP_001681770.1	DEEDAYHMKSFFHQANPGSYVDDHKRLIRK	170
XP_817467.1	DEEDAFHMKKFFKGPNPGLYVAANRQLVRQQNSAAAAVTGMAALQRNGGTAPPPPPPSSS	200
XP_828529.1	DEEDAYHMKRFFKGTNPGFYVTESRQLVRQPNT * ***: **	173
NP 011877.1	TYRRMGIAENLMRQALFALREVHQAEYVSLHVRQSNRAALHLYRDTLAFEVLSIEKSYYQ	180
NP 003482.1	SHRRLGLAQKLMDQASRAMIENFNAKYVSLHVRKSNRAALHLYSNTLNFQISEVEPKYYA	139
xp_001681770.1	${\tt SHRKLGIASRVMRATMKEMDAEYGAHYCSLHVRKTNDAALHLYQDTLGFRCVGVEEKYYM$	140
XP 817467.1	THRRLGIASRVMRASMKEMEKEYDANYCSLHVRKTNDAALHLYQETLGFRCANVEKGYYV	140
XP 828529.1	THRRLGIASRVMNAALHEMEHEYDANFCSLHVRKTNDAALHLYONTLNFRCANVESKYYV	140
-	::*::*:*:* : : . *.: *****::* ***** <sup>*</sup> :** *. :* **	
NP_011877.1	DGEDAYAMKKVLK	193
NP_003482.1	DGEDAYAMKR	149
xp_001681770.1	DEEDAYHMKSFFHQANPGSYVDDHKRLIRK	170
XP_817467.1	DEEDAFHMKKFFKGPNPGLYVAANRQLVRQQNSAAAAVTGMAALQRNGGTAPPPPPPSSS	200
XP_828529.1	DEEDAYHMKRFFKGTNPGFYVTESRQLVRQPNT	173
	D	
XP_001686706.1	YSNREYSKALRTSECILRVVPDHVDTFAGRGLVLYNMERQEEGYESIKQAILLNP	55
XP_807954.1	FDAREYAKALRCADAILAVIPSHADTIAMRGLTLHHLDRREEGHLAIKEAIELNI	55
XP_822811.1	FDAREYAKGLRTADSILSVVPNHADTLALKGLTLHHMGRKEEGREIIESALGFND	55
NP_476516.1	YEHKQYRNGLKFCKQILSNPKFAEHGETLAMKGLTLNCLGKKEEAYELVRRGLRNDL	57
EDN60314.1	YEGKQYKKSLKLLDAILKKDGSHVDSLALKGLDLYSVGEKDDAASYVANAIRKIEGAS :. ::* :.*: . *** :::* :** * : .:: : .:	58
XP_001686706.1	KSMVAWHALGMCQRLDKKFGEAVKAFKRALTFDPANTEVLRDLASACIQVRDWPLFLEAR	115
XP 807954.1	NSTMAWHSLGMCHRAEKNYPEAIKAFKKAHQTDPTNANVLRDLSSVCVQVRDWEQFVETR	115
XP 822811.1	TSTVVWHSLGMCHRADDNHVEALHAFQKAHEYGPSNVNVLRDISSICVQLREWEQFVDVR	115
NP 476516.1	KSHVCWHVYGLLORSDKKYDEAIKCYRNALKWDKDNLOILRDLSLLOIOMRDLEGYRETR	117
EDN60314.1	ASPICCHVLGIYMRNTKEYKESIKWFTAALNNGSTNKQIYRDLATLQSQIGDFKNALVSR *: * *: * *::: * . *:: **: *: *	118
XP 001686706.1	EKMVTAKASVRANWVALSCGHRILGHSRIAAAVMDTMTSIMDAGDNPVEVSEAQLYR	172
XP_807954.1	QKMVTLKAGVRANWIALSCGHRMMGHTELAAAVIDVMTSIMDAGENVVEKSEVFLYL	172
XP 822811.1	RKMVTLRPGVRANWIALSCGHRMLGNKELAAAVIDVMTTIMEAGDNRAEKSEVRLYQ	172
NP_476516.1	YQLLQLRPAQRASWIGYAIAYHLLEDYEMAAKILEEFRKTQ-QTSPDKVDYEYSELLLYQ	176
EDN60314.1	KKYWEAFLGYRANWTSLAVAQDVNGERQQAINTLSQFEKLAEGKISDSEKYEHSECLMYK	178

**Supplementary Figure 1:** Alignment of TcNaa35/TcNaa38 and TcNaa10/TcNaa15 with orthologous sequences from other eukaryotes. **A;** Comparison of predicted TcNaa35 with other proteins. The tick line indicates predicted Mak10 domain region. The most conserved aa are represented by a star (\*). Note that only part of the alignment is displayed. Polypeptides used are: *Leishmania major* (XP\_001682355.1), *T. cruzi* (XP\_814406.1), *T. brucei* (XP\_844906.1), Plant (NP\_001118295.1), human (SP|Q5VZE5) and Yeast (NP\_579858.1). **B;** TcNaa38 sequence alignment with selected proteins. \* Denote the most conserved aa. Sequences included in the alignment are: Yeast (NP\_010946.3), Human (NP\_001317040.1), *Leishmania major* (XP\_003722006.1), *T. cruzi* (XP-808107.1) and *T. brucei* (XP\_951644.1)

С

C; Comparison of TcNaa10 sequence with selected eukaryotes. The over lined indicates the consensus sequence RXXGXA for NatA, where acetyl –CoA binds. The two arrows indicate the active sites and a symbol  $\ddagger$  is the predicated possible lysine auto acetylation site. Used sequences in the alignment are: Yeast (NP\_011877.1), Human (NP\_003482.1), *Leishmania major* (XP\_001681770.1), *T. cruzi* (XP\_817467.1) and *T. brucei* (XP\_828529.1). **D**; TcNaa15 sequence comparison with putative homologues from other species. Polypeptides used in the alignment are: *Leishmania major* (XP\_001686706.1), *T. cruzi* (XP\_807954.1), *T. brucei* (XP\_822811.1), Human (NP\_476516.1 and Yeast (END60314.1. \* Indicates residues, which are highly conserved.



**Supplementary Figure 2:** Recombinant protein production and analysis on 10 % SDS-PAGE. **A;** Recombinant GST-TcNaa35. **B;** GST-TcNaa38. **C;** GST-TcNaa10 and **D;** GST-TcNaa15. Samples loaded in the different lanes are as follows, Lane1; Molecular mass in kDa. Lane 2; Non-induced (NI). Lane 3; Induced (IND), Lane 4; Pellet (P). Lane 5; Supernatant (Sup). Lane 6; Semi Purified (S/Purified).



**Supplementary Figure 3:** Localization of TcNaa38 and TcNaa15. Number 1 to 5 denotes, Midlog epimastigotes, Stationary epimastogotes, Metacyclic trypomastigotes, Trypomastigotes, and Amastigotes, respectively. *T. cruzi* four developmental stages were immunolabelled with, **A**; anti-TcNaa38 and **B**; anti-TcNaa15. The nucleus and kinetoplast were visualized using DAPI stain (N+K), scale bars =  $5 \mu m$ .



Supplementary Figure 4: Localization of TcNaa30 and TcNaa38 in internal amastigotes. Parasites were allowed to invade Vero cells and divide. Cells were immunolabelled with anti - TcNaa30 and anti- TcNaa38 (green) and counter labeled with DAPI (blue) to visualize the nucleus and kinetoplast, scale bars =  $10 \mu M$ .







**Supplementary Figure 5:** Phenotype of the knock down of putative *T. brucei* Naa30 by RNAi showing growth curves and mRNA level, **A**; Wild type, **B**; Transfected, **C**; The parasite growth of the transfectants compared to that of the wild type (blue). Cells at a density of  $2.5 \times 10^4$ /ml were grown in the absence (**-Tet**) or presence (**+Tet**) of tetracycline (100ng/ml) over a period of 72h. The result is a representative of the mean parasite growth of *T. b. brucei* 427 obtained from three independent experiments. **D**; Gene expression analysis of wild type (W), non-induced (-) and induced (+) cells using Reverse Transcriptase PCR. The products were separated on a 2% agarose gel alongside a 1kb DNA ladder and visualized using ethidium bromide staining. Shown is day 0-48h and day 72h post-RNAi induction. Actin (700bp) was amplified as an internal control alongside NatC catalytic subunit (573bp). The cell densities used for Day 0, 24, 48 and 72h from which RNA was isolated were  $1 \times 10^5$ /ml;  $2.73 \times 10^5$ /ml;  $3.75 \times 10^5$ /ml and  $4.7 \times 10^5$ /ml, respectively.